[Skip to Content]
[Skip to Content Landing]
Views 258
Citations 0
Viewpoint
July 6, 2017

Conflict of Interest, Conflicting Interests, and Effective Collaboration Between Academia and Industry on Preclinical and Clinical Cancer Research

Author Affiliations
  • 1Department of Oncology, Pfizer, New York, New York
  • 2Department of Internal Medicine, UT Southwestern School of Medicine, Dallas, Texas
JAMA Oncol. Published online July 6, 2017. doi:10.1001/jamaoncol.2017.1822

In the modern era of patient-centered drug development, the only way to translate biological and genomic discoveries into clinically meaningful therapies is through partnerships among academia, industry, and government. To ensure that the integrity of the research is beyond reproach, investigators who engage in such collaborations are expected to disclose relationships that could potentially have an influence on the results or interpretation of the research project.1,2 Herein, we examine several dimensions of conflicts of interest (COIs), describe the distinct entity of conflicting interests, and describe how they may affect clinical cancer research.

First Page Preview View Large
First page PDF preview
First page PDF preview
×